Thursday, September 23, 2010

Press Conference Schedule: AIDS VACCINE 2010

AIDS Vaccine 2010 Press Conference Schedule 22 Sep 10 / SUBJECT TO CHANGE 1
AIDS Vaccine 2010
All press conferences will be held in the Magnolia Room (Level M2) of the Omni Hotel at CNN Center.
Embargoes on research presented in AIDS Vaccine 2010 press conferences lift at the end of the press
conference or at the end of the conference session in which the study is presented, whichever is earlier
Tuesday, 28 September, 3:15 – 4:15 pm (15.15 – 16.15)
State of the Field and Overview of AIDS Vaccine 2010
Eric Hunter, Center for AIDS Research, Emory University, Atlanta, GA, USA
Future directions of HIV vaccine research
Alan Bernstein, Global HIV Vaccine Enterprise New York, NY, USA
The path to an HIV vaccine: Follow the science
Anthony Fauci, National Institute of Allergy and Infectious Diseases, US National Institutes of
Health, Bethesda, MD, USA
The critical role of Africa in the development of an AIDS vaccine
Malegapuru William Mkgoba, University of KwaZulu‐Natal, KwaZulu‐Natal,
South Africa
Status of the US epidemic and CDC support for HIV prevention research
Thomas Frieden, Centers for Disease Control and Prevention, Atlanta, GA, USA
The role of community in vaccine development
Dazon Dixon Diallo, Sisterlove, Inc., Atlanta, GA, USA
AIDS Vaccine 2010 Press Conference Schedule 22 Sep 10 / SUBJECT TO CHANGE 2
Wednesday, 29 September, 12:00 – 1:00 pm (12.00 – 13.00)
Progress Toward an HIV Vaccine
Alan Bernstein, Global HIV Vaccine Enterprise New York, NY, USA
Overview of the 2010 Global HIV Vaccine Enterprise Scientific Strategic Plan
Jose Esparza, The Bill & Melinda Gates Foundation, Seattle, WA, USA (TBC)
Catherine Hankins, UNAIDS, Geneva, Switzerland
Glenda Gray, HIV Vaccine Trials Network, Johannesburg, South Africa
Advances in Basic Science
Affinity maturation allows VRC01‐like antibodies to converge on a common mode of effective
HIV‐1 neutralization (OA05.06 LB)
Peter Kwong, Vaccine Research Center, NIAID/NIH Bethesda, MD, USA
Clues from the isolation and structural analysis of broadly neutralizing anti‐HIV‐1 antibodies
John Mascola, Vaccine Research Center, NIAID, NIH Bethesda, Maryland, USA (TBC)
AIDS Vaccine 2010 Press Conference Schedule 22 Sep 10 / SUBJECT TO CHANGE 3
Thursday, 30 September, 12:30 – 1:30 pm (12.30 – 13.30)
Challenges in HIV Prevention Research
Linda‐Gail Bekker, Desmond Tutu HIV Foundation, Cape Town, South Africa
Cost‐per‐HIV infection averted in Africa by couples’ HIV testing vs antiretroviral treatment: HIV
prevention in a 2010 global economy (OA07.06)
Susan Allen, Emory University/Rwanda Zambia HIV Research Group, Atlanta, GA, USA (TBC)
Innate‐mucosal immune interactions during acute infection (PL02.01)
Ashley Haase, Department of Microbiology, University of Minnesota Medical School,
Minneapolis, MN, USA (TBC)
Correlates of immunity: RV144 – Lessons learned (PL03.01)
Nelson Michael, US Military HIV Research Program (MHRP)/Walter Reed Army Institute of
Research, Rockville, MD, USA
The need for more efficient efficacy trials of HIV vaccines (PL03.03)
Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Impact of biomedical prevention approaches on the implementation of HIV vaccine efficacy
trials (PL03.05)
Salim Abdool Karim, CAPRISA, University of KwaZulu‐Natal, South Africa
Making GPP come alive: Experiences from implementing Good Participatory Practice
Guidelines for biomedical HIV prevention trials (S08.04)
Mitchell Warren, AVAC: Global Advocacy for HIV Prevention, New York, NY, USA

No comments: